Earnings Calls

Citigroup continued executing its multi-year organizational simplification, completing the separation of its Mexico consumer banking unit (Banamex) IPO filing in Q1 2026. The company announced an additional $1 billion in cost savings targets for 2026 and expanded its services division with new treasury management clients. CEO Jane Fraser reiterated medium-term ROTCE targets of 11-12% at the company's investor day in February.

Net interest income trajectory and updated expense guidance will be the key figures, given Citi's ongoing transformation costs. Commentary on credit card delinquency trends and any revision to the ROTCE timeline will move shares.

Johnson & Johnson reached a revised $10 billion talc litigation settlement framework in early 2026, with final court approval still pending. The company completed its acquisition of Intra-Cellular Therapies for approximately $15 billion, adding the schizophrenia drug Caplyta to its neuroscience portfolio. JNJ also received FDA approval for a new indication for Tremfya in ulcerative colitis during Q1.

Investors will focus on MedTech segment organic growth and the early integration trajectory of Intra-Cellular Therapies. Any update on the talc settlement's judicial status is material.

JPMorgan reported record full-year 2025 revenue and signaled continued investment banking market share gains heading into 2026. CEO Jamie Dimon warned in his annual shareholder letter about elevated geopolitical risks and potential credit normalization. The bank increased its quarterly dividend to $1.40 per share in Q1 2026 and continued share repurchases at an accelerated pace.

Net interest income guidance for full-year 2026 is the single most important figure, as consensus has widened. Investment banking and trading revenue relative to the strong Q1 2025 comp will set the tone for the sector.

Wells Fargo received partial relief on its Fed asset cap in late 2025, allowing limited balance sheet growth in certain business lines for the first time since 2018. The bank continued its aggressive cost reduction program, targeting a sub-60% efficiency ratio by year-end 2026. CEO Charlie Scharf highlighted improved returns in the corporate and investment banking division at a February conference.

Progress on the efficiency ratio and any commentary on further asset cap relief will dominate the narrative. Net interest income relative to the full-year guide and credit loss provisions in consumer lending are the key numbers.

Bank of America has beaten EPS estimates for four consecutive quarters, driven by expanding net interest income as its large fixed-rate securities portfolio reprices higher. The bank reported strong Q4 2025 wealth management inflows and guided for continued NII growth into 2026. BAC also announced a $3.5 billion accelerated share repurchase program in early Q1.

The NII figure and full-year NII guidance are the primary catalysts, as BAC has the highest asset sensitivity among large peers. Consumer credit quality trends in the card and auto portfolios will also be closely watched.

Kinder Morgan expanded its natural gas pipeline capacity commitments, signing new long-term contracts tied to LNG export facility expansions along the Gulf Coast. The company raised its 2026 capital expenditure budget to $2.8 billion, primarily for natural gas infrastructure buildout driven by data center and AI-related power demand. KMI increased its annual dividend by 2% in January.

Watch for updated contracted backlog figures and any commentary on data center-related natural gas demand materializing into firm transport agreements. DCF per share relative to the dividend coverage ratio is the key metric.

Morgan Stanley has delivered four consecutive EPS beats, powered by strength in wealth management and a rebound in investment banking fees. The firm surpassed $7 trillion in client assets under management in late 2025, hitting its long-term target ahead of schedule. New CEO Ted Pick, now over a year into the role, outlined updated growth targets at the firm's January strategic update.

Wealth management net new assets and pre-tax margin are the headline figures, as they underpin the valuation premium. Investment banking pipeline commentary and equity trading revenue relative to elevated Q1 2025 comps will also matter.

PNC Financial has beaten estimates for four straight quarters, benefiting from disciplined expense management and steady loan growth in its mid-Atlantic and Southeast footprint. The bank completed its technology platform modernization initiative in Q4 2025, which management expects to drive further operating leverage. PNC also expanded its corporate banking presence in Dallas and Houston during Q1.

Net interest income and the NII outlook for the rest of 2026 will be the primary focus, along with commentary on commercial loan demand trends. Any uptick in commercial real estate provisions would draw scrutiny.

Abbott Laboratories received FDA clearance for its next-generation continuous glucose monitor, Lingo, for over-the-counter consumer use in early 2026, expanding its diabetes care addressable market. The company's medical devices segment showed accelerating organic growth through Q4 2025, led by structural heart and electrophysiology. Abbott also faced headwinds from a stronger U.S. dollar impacting international revenue.

Organic growth in the medical devices segment and early Lingo OTC sales traction are the two figures to watch. Updated full-year 2026 EPS guidance relative to the $5.47 consensus will set the tone.

Netflix stopped reporting subscriber numbers in 2025, shifting investor focus entirely to revenue and operating margins. The company's ad-supported tier surpassed 70 million global monthly active users by year-end 2025, accelerating advertising revenue growth. Netflix also completed a slate of live sports events including NFL Christmas games and WWE Raw, expanding its content programming mix.

Ad-tier revenue growth and operating margin are now the two defining metrics since subscriber counts are no longer disclosed. Any commentary on content spending trajectory for 2026-2027 and live sports ROI will be closely parsed.

Travelers reported strong underwriting results through 2025, aided by firming commercial insurance pricing and below-average catastrophe losses in Q4. The company increased its reserve position heading into 2026 Atlantic hurricane season forecasts, which call for above-average activity. Travelers raised its dividend by 5% in February and continued an active buyback program.

The combined ratio and catastrophe loss figure for Q1 will be the primary movers, along with commentary on commercial pricing trends and reserve adequacy. Prior-year reserve development direction is always material.

U.S. Bancorp has beaten EPS estimates for four straight quarters, driven by improving operating leverage following the full integration of Union Bank. The company achieved its targeted $900 million in merger-related cost synergies by Q4 2025, ahead of schedule. USB also launched an expanded payments and treasury management platform aimed at mid-market commercial clients in Q1 2026.

Net interest income trajectory and the fee income mix from payments will be the key data points. Any commentary on further expense savings beyond the Union Bank synergy target would be incremental.